JP2024540322A5 - - Google Patents

Info

Publication number
JP2024540322A5
JP2024540322A5 JP2024526682A JP2024526682A JP2024540322A5 JP 2024540322 A5 JP2024540322 A5 JP 2024540322A5 JP 2024526682 A JP2024526682 A JP 2024526682A JP 2024526682 A JP2024526682 A JP 2024526682A JP 2024540322 A5 JP2024540322 A5 JP 2024540322A5
Authority
JP
Japan
Prior art keywords
amino acid
cell epitopes
human
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526682A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540322A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/080679 external-priority patent/WO2023079001A1/en
Publication of JP2024540322A publication Critical patent/JP2024540322A/ja
Publication of JP2024540322A5 publication Critical patent/JP2024540322A5/ja
Pending legal-status Critical Current

Links

JP2024526682A 2021-11-03 2022-11-03 SARS-CoV-2によって引き起こされる疾患の予防及び処置に使用するための免疫原性構築物及びワクチン Pending JP2024540322A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163275015P 2021-11-03 2021-11-03
US63/275,015 2021-11-03
US202263377087P 2022-09-26 2022-09-26
US63/377,087 2022-09-26
PCT/EP2022/080679 WO2023079001A1 (en) 2021-11-03 2022-11-03 Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2

Publications (2)

Publication Number Publication Date
JP2024540322A JP2024540322A (ja) 2024-10-31
JP2024540322A5 true JP2024540322A5 (cg-RX-API-DMAC10.html) 2025-11-11

Family

ID=84365420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024526682A Pending JP2024540322A (ja) 2021-11-03 2022-11-03 SARS-CoV-2によって引き起こされる疾患の予防及び処置に使用するための免疫原性構築物及びワクチン

Country Status (9)

Country Link
US (1) US20250049910A1 (cg-RX-API-DMAC10.html)
EP (1) EP4426344A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024540322A (cg-RX-API-DMAC10.html)
KR (1) KR20240110821A (cg-RX-API-DMAC10.html)
AU (1) AU2022381515A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235174A1 (cg-RX-API-DMAC10.html)
IL (1) IL312539A (cg-RX-API-DMAC10.html)
MX (1) MX2024005408A (cg-RX-API-DMAC10.html)
WO (1) WO2023079001A1 (cg-RX-API-DMAC10.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215489B2 (en) 2003-02-25 2010-07-15 Nykode Therapeutics ASA Modified antibody
WO2011161244A1 (en) 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs
EP3533462A1 (en) 2011-12-21 2019-09-04 Vaccibody AS Vaccines against hpv
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
CN113631185A (zh) 2019-02-27 2021-11-09 尼克塔治疗公司 用于治疗癌症的免疫治疗组合
PH12022552164A1 (en) * 2020-02-19 2023-11-29 United Biomedical Inc Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19)
US20230218741A1 (en) * 2020-03-31 2023-07-13 The Children's Hospital Of Philadelphia Sars-cov-2 vaccines for population-scale immunity

Similar Documents

Publication Publication Date Title
Han et al. IL-15: IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization
ES3064850T3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2023524054A5 (cg-RX-API-DMAC10.html)
ES2210255T3 (es) Metodos para mejorar la actividad biologica de quimiocinas.
JP2022017499A (ja) 治療用抗癌ネオエピトープワクチン
CA2304254A1 (en) Trimerising module
JP2019123719A (ja) インターロイキン−10を疾病及び疾患の治療に用いる方法
JP2013513377A5 (cg-RX-API-DMAC10.html)
RU2012129208A (ru) Конъюгаты и композиции для иммунотерапии и противоопухолевого лечения
JP2022541657A5 (cg-RX-API-DMAC10.html)
JP2020528743A5 (cg-RX-API-DMAC10.html)
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
WO2008000516B1 (en) IMPROVED sgp130Fc DIMERS
WO2004026897A1 (ja) Wt1置換型ペプチド
JP2023528207A5 (cg-RX-API-DMAC10.html)
WO2011101332A1 (en) Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
JP2023522588A5 (cg-RX-API-DMAC10.html)
EP2145898A1 (en) Anti-amyloid immunogenic compositions, methods and uses
JP2024516613A5 (cg-RX-API-DMAC10.html)
WO2022141771A1 (zh) 一种长效化白介素15融合蛋白及其制备方法和应用
ES2217199T3 (es) Mutantes de quimioquinas en el tratamiento de la esclerosis multiple.
KR101101004B1 (ko) 신규한 펩티드 및 그들의 치료 용도
CN111499762B (zh) 一种包含PDGFRβ特异性亲和体和TNFα的融合蛋白及其用途
JP2022513626A5 (cg-RX-API-DMAC10.html)
TWI905155B (zh) 包含 il-2蛋白及cd80蛋白片段或其變異體的融合蛋白及其用途